Section Arrow
Quote
AGEN.NASDAQ
- Agenus
Quotes are at least 15-min delayed:2026/04/07 10:32 EDT
Regular Hours
Last
 3.66
-0.11 (-2.92%)
Day High 
3.7898 
Prev. Close
3.77 
1-M High
4.1 
Volume 
212.14K 
Bid
3.65
Ask
3.66
Day Low
3.58 
Open
3.77 
1-M Low
2.9 
Market Cap 
136.25M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.47 
20-SMA 3.46 
50-SMA 3.22 
52-W High 7.34 
52-W Low 1.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/-0.73
Enterprise Value
146.36M
Balance Sheet
Book Value Per Share
-7.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
114.20M
Operating Revenue Per Share
2.75
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LNAILunai Bioworks Inc.0.3851+0.1031+36.56%-- 
SILOSilo Pharma0.4837+0.1279+35.95%-- 
TERNTerns Pharmaceuticals52.61-0.17-0.32%-- 
CUECue Biopharma0.1804+0.0034+1.92%-- 
QNCXQuince Therapeutics0.0963+0.0088+10.06%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.